Trials / Terminated
TerminatedNCT00902525
Zevalin Twice in Aggressive Non-Hodgkin Lymphoma
Two Repeated Doses of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) as Salvage Treatment for Patients With Relapsed or Refractory Aggressive B-cell Lymphoma: a Phase II Study.
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 25 (actual)
- Sponsor
- Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Despite of the availability of treatment for this disease, this study is justified because no known therapies are really curative and it is necessary to look for new treatment options to improve the clinical outcome and prognosis of relapsed aggressive lymphoma. This study is designed for patients not eligible for high-dose chemotherapy and autologous stem cells transplantation.
Detailed description
The objectives of this study are to evaluate the efficacy and safety of two sequential doses of 90Y-Ibritumomab Tiuxetan administered after salvage chemotherapy in patients with relapsed/refractory aggressive lymphoma non-eligible for HDC and ASCT.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | 90Y-Ibritumomab Tiuxetan | All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2009-01-01
- Completion
- 2011-09-01
- First posted
- 2009-05-15
- Last updated
- 2012-12-31
Locations
12 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT00902525. Inclusion in this directory is not an endorsement.